Why lung cancer doesn't respond well to immunotherapy.

The researchers found that T cells in lymph nodes that drain from the lung tumors did encounter dendritic cells and recognize the tumor antigens displayed by those cells. The lymph nodes are where "killer T cells" encounter dendritic cells, which present antigens (tumor proteins) and help to activate the T cells. Keywords: Antigen-Presenting Cells; Biological Factors; Cancer; Cytokines; Dendritic Cells; Drugs and Therapies; Genetics; Health and Medicine; Hemic and Immune Systems; Immunology; Immunotherapy; Intercellular Signaling Peptides and Proteins; Interferon-gamma; Interferons; Lung Cancer; Lung Diseases and Conditions; Lung Neoplasms; Lymph Nodes; Lymphoid Tissue; Lymphokines; Macrophage-Activating Factors; Massachusetts Institute of Technology; Mononuclear Phagocyte System; Oncology; Peptides; Proteins; Technology EN Antigen-Presenting Cells Biological Factors Cancer Cytokines Dendritic Cells Drugs and Therapies Genetics Health and Medicine Hemic and Immune Systems Immunology Immunotherapy Intercellular Signaling Peptides and Proteins Interferon-gamma Interferons Lung Cancer Lung Diseases and Conditions Lung Neoplasms Lymph Nodes Lymphoid Tissue Lymphokines Macrophage-Activating Factors Massachusetts Institute of Technology Mononuclear Phagocyte System Oncology Peptides Proteins Technology 2023 FEB 21 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- CAMBRIDGE, MA -- Immunotherapy - drug treatment that stimulates the immune system to attack tumors - works well against some types of cancer, but it has shown mixed success against lung cancer. [Extracted from the article]